公开(公告)号：US5846742A

公开(公告)日：1998-12-08

申请号：US800867

申请日：1997-02-14

申请人： Peter E. Lipsky ,  Xue-Lian Tao ,  Jian Cai ,  William J. Kovacs ,  Nancy J. Olson

发明人： Peter E. Lipsky ,  Xue-Lian Tao ,  Jian Cai ,  William J. Kovacs ,  Nancy J. Olson

IPC分类号： A61K31/365 ,  A61K31/44 ,  A61K31/565 ,  A61K31/74 ,  A61K36/00 ,  A61K36/37 ,  C12Q1/00 ,  G01N33/566 ,  C12N5/00 ,  C12Q1/48 ,  C12Q1/66

CPC分类号： A61K31/565 ,  A61K31/365 ,  A61K31/44 ,  A61K36/37 ,  Y10S514/821 ,  Y10S514/825 ,  Y10S514/886

摘要： The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.

摘要翻译： 本发明提供了雷公藤提取物及其纯化组分用于治疗炎症或免疫疾病以及伴随的缺乏类固醇效应的用途。 该植物（T2）的提取物与糖皮质激素受体结合，并且竞争性抑制糖皮质激素介导的细胞过程，例如与糖皮质激素受体结合的地塞米松，糖皮质激素介导的靶基因活化，地塞米松依赖性细胞生长，伴随环氧合酶-2诱导的抑制; 炎症过程如前列腺素E2的产生。 T2提取物组分雷公藤内酯和tripdiolide是有效的抑制剂。 本文方法提供的特别的优点是治疗或预防炎症和伴随的缺乏甾体激动剂效应和NSAID副作用。 通过本发明方法可治疗的病症包括炎症和免疫疾病，包括自身免疫性疾病。